[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-plaque-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-plaque-psoriasis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100637755","comparison-of-methotrexate-and-tofacitinib-in-chronic-plaque-psoriasis-100637755",false,"NCT07581418","Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","Comparison of Outcome Between Oral Methotrexate and Tofacitinib in Treatment of Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Eligible participants will comprise adults aged 18 to 70 years, of either gender, with moderate to severe plaque psoriasis defined by a Psoriasis Area and Severity Index (PASI) score greater than 10. A minimum disease duration of 6 months will be required. In addition, enrolment will be limited to patients whose psoriasis has shown inadequate response to at least one topical therapy despite a treatment duration of at least 4 weeks\n\nExclusion Criteria:\n\n* Participants with non-plaque variants of psoriasis or any other clinically significant dermatological condition that could confound the assessment of psoriasis severity. Recent exposure to anti psoriatic therapy including systemic or biologic treatment within the preceding 4 weeks or topical treatment within the preceding 2 weeks. Individuals with known hypersensitivity to, or contraindications for, either methotrexate or tofacitinib. Patients with a history of significant hepatic, renal, hematologic, gastrointestinal, or immune system disorders. Pregnant or breastfeeding women. Patients unavoidable prolonged sun or ultraviolet exposure. Patients with a history of alcohol abuse, or other conditions that contraindicate methotrexate use..","ALL","18 Years","70 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.",[27],"Chronic Plaque Psoriasis",[29,27,30,31,32,33],"Psoriasis","Methotrexate","Tofacitinib","Randomized Controlled Trial","Systemic Therapy","NOT_YET_RECRUITING","2026-05-06",{"date":37,"type":38},"2026-05-12","ACTUAL",{"date":40,"type":21},"2026-06-01",{"date":42,"type":21},"2026-12-01",{"name":44,"class":45},"Pak Emirates Military Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100618885","early-phase-1-to-check-comparison-of-apremilast-and-methotrexate-efficacy-in-patients-with-moderate-to-severe-plaque-psoriasis-presented-to-tertiary-care-hospital-100618885","NCT07337434","To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital","Comparison of Efficacy of Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\nPatients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.\n\nExclusion Criteria:\n\nPregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs",true,"60 Years",{"count":56,"type":21},106,[58],"EARLY_PHASE1","This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.",[27],"RECRUITING","2026-01-07",{"date":64,"type":38},"2026-01-13",{"date":66,"type":21},"2025-12-25",{"date":68,"type":21},"2026-06-25",{"name":70,"class":71},"Syeda Sana Zaman","OTHER_GOV",1]